Financhill
Back

iSpecimen Quote, Financials, Valuation and Earnings

iSpecimen Price Quote

$4.02
+3.83 (+1985.06%)
(Updated: September 16, 2024 at 2:55 PM ET)

iSpecimen Key Stats

Sell
2
iSpecimen (ISPC) is a Sell

Day range:
$0.19 - $0.22
52-week range:
$0.18 - $0.79
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.18
P/B ratio:
0.41%

Volume:
1.8M
Avg. volume:
929.6K
1-year change:
-70.7%
Market cap:
$2.5M
Revenue:
$9.9M
EPS:
$-1.08

How Much Does iSpecimen Make?

  • How Much Are iSpecimen's Sales Annually?
    ISPC Revenues are $9.9M
  • How Much Profit Does iSpecimen's Make A Year?
    ISPC net income is -$11.1M

Is iSpecimen Growing As A Company?

  • What Is iSpecimen's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.76%
  • What Is iSpecimen's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

iSpecimen Stock Price Performance

  • Did iSpecimen Stock Go Up Last Month?
    iSpecimen share price went down by -29.64% last month
  • Did ISPC's Share Price Rise Over The Last Year?
    ISPC share price fell by -70.7% over the past 1 year

What Is iSpecimen 52-Week High & Low?

  • What Is iSpecimen’s 52-Week High Share Price?
    iSpecimen has traded as high as $0.79 over the past 52 weeks
  • What Is iSpecimen’s 52-Week Low Share Price?
    iSpecimen has traded as low as $0.18 over the past 52 weeks

iSpecimen Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy iSpecimen?

  • How Much Debt Does iSpecimen Have?
    Total long term debt quarterly is $0
  • How Much Cash Does iSpecimen Have?
    Cash and short term investments quarterly total is $2.2M
  • What Is iSpecimen’s Book Value Per Share?
    Book value per share is 0.47

Is iSpecimen Cash Flow Positive?

  • What Is ISPC Cash Flow From Operations?
    Cash flow from operations (TTM) is -$4.9M
  • What Is iSpecimen’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $1.2M
  • What Is iSpecimen’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $3.9M

iSpecimen Return On Invested Capital

  • Is Management Doing A Good Job?
    ISPC return on invested capital is -101.83%
  • What Is iSpecimen Return On Assets?
    ROA measures how assets are converting to revenues and is -68.79%
  • What Is ISPC Return On Equity?
    ROE is a measure of profitability and is -101.83%

iSpecimen Earnings Date & Stock Price

  • What Is iSpecimen's Stock Price Today?
    A single share of ISPC can be purchased today for 0.19
  • What Is iSpecimen’s Stock Symbol?
    iSpecimen trades on the nasdaq under the ticker symbol: ISPC
  • When Is iSpecimen’s Next Earnings Date?
    The next quarterly earnings date for iSpecimen is scheduled on September 16, 2024
  • When Is ISPC's next ex-dividend date?
    iSpecimen's next ex-dividend date is September 16, 2024
  • How To Buy iSpecimen Stock?
    You can buy iSpecimen shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

iSpecimen Competitors

  • Who Are iSpecimen's Competitors?
    Below is a list of companies who compete with iSpecimen or are related in some way:
    • Delcath Systems Inc (DCTH)
    • DermTech Inc (DMTKQ)
    • 23andMe Holding Co (ME)
    • Progyny Inc (PGNY)
    • RadNet Inc (RDNT)

iSpecimen Dividend Yield

  • What Is ISPC Dividend Yield?
    iSpecimen’s dividend yield currently is 0%
  • What Is iSpecimen’s Payout Ratio?
    iSpecimen’s payout ratio is 0%
  • When Did iSpecimen Last Pay A Dividend?
    The latest dividend pay date is September 16, 2024
  • What Is iSpecimen’s Dividend Per Share?
    iSpecimen pays a dividend of $0.00 per share

iSpecimen Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 76.21% -0.6%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 3.00
Upside from Last Price: 1456.02%

Major Shareholders

  • How many ISPC shares are owned by institutional investors?
    387.8K ISPC shares are owned by institutional investors
  • How many ISPC shares are owned by insiders?
    2.1M ISPC shares are owned by insiders